Francesca Alvarez Calderon, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematologic Neoplasms | 2 | 2024 | 1896 | 0.580 |
Why?
|
| Oligomycins | 1 | 2014 | 20 | 0.500 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 53 | 0.480 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2016 | 495 | 0.480 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 686 | 0.400 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2015 | 2425 | 0.320 |
Why?
|
| RNA Interference | 2 | 2014 | 2832 | 0.300 |
Why?
|
| Mitochondria | 2 | 2015 | 3624 | 0.240 |
Why?
|
| OX40 Ligand | 1 | 2024 | 55 | 0.240 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2024 | 84 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 5305 | 0.190 |
Why?
|
| Neoplasms | 2 | 2024 | 22173 | 0.190 |
Why?
|
| Antigen-Presenting Cells | 1 | 2024 | 964 | 0.180 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2014 | 431 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 5672 | 0.170 |
Why?
|
| Immunity, Cellular | 1 | 2024 | 1560 | 0.150 |
Why?
|
| RNA, Small Interfering | 4 | 2016 | 3430 | 0.150 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 1827 | 0.130 |
Why?
|
| Ketone Oxidoreductases | 1 | 2014 | 5 | 0.120 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 11 | 0.120 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2016 | 210 | 0.120 |
Why?
|
| Superoxides | 1 | 2014 | 387 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 295 | 0.110 |
Why?
|
| Luciferases, Firefly | 1 | 2013 | 37 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 651 | 0.110 |
Why?
|
| Leukemia, Experimental | 1 | 2013 | 225 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 4369 | 0.090 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 342 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 3080 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 4580 | 0.090 |
Why?
|
| Philadelphia Chromosome | 1 | 2010 | 117 | 0.090 |
Why?
|
| Photons | 1 | 2013 | 589 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 976 | 0.080 |
Why?
|
| Animals | 8 | 2024 | 168475 | 0.080 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 389 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 9177 | 0.070 |
Why?
|
| Mice | 5 | 2024 | 81539 | 0.070 |
Why?
|
| Carotenoids | 1 | 2009 | 621 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2010 | 718 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 18255 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 16990 | 0.050 |
Why?
|
| Apoptosis | 2 | 2014 | 9490 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 3615 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2009 | 5439 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2014 | 14417 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 22174 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2024 | 1616 | 0.040 |
Why?
|
| Calcium | 1 | 2010 | 5722 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5821 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 11742 | 0.030 |
Why?
|
| Humans | 8 | 2024 | 761596 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2016 | 247 | 0.030 |
Why?
|
| Hydrazines | 1 | 2016 | 224 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 6131 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2024 | 5485 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2024 | 10451 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 529 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2013 | 86 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 3029 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2231 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3605 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2009 | 595 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2010 | 778 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 2626 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 5791 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6312 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 1880 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 6374 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 1371 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2016 | 10090 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4576 | 0.010 |
Why?
|
| Thiazoles | 1 | 2010 | 1517 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2010 | 5035 | 0.010 |
Why?
|
| Female | 3 | 2016 | 392705 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2016 | 23447 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2010 | 5870 | 0.010 |
Why?
|
| Piperazines | 1 | 2010 | 2523 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2010 | 3028 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4176 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 9001 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 7396 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 12794 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13642 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 220921 | 0.000 |
Why?
|